secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2024-06-05T23:59:59+00:00
Accession:  0001193125-24-154636
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir reports high virologic response in Phase 2 SOLSTICE hepatitis delta trial
-----------------------------------------------------------------------------

- De novo tobevibart+elebsiran combination: 64% (7/11) combined endpoint at week 24.
- Tobevibart monotherapy: 55% (6/11) combined endpoint at week 24.
- No serious adverse events, no ALT flares; majority of AEs Grade 1-2 and transient.
- Company to report additional 24-week data for all ~60 participants in Q4 2024.
- Data to be presented at EASL Congress on June 8, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000119312524154636/0001193125-24-154636-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000119312524154636/d819044d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-154636

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer